Recursion registers 4.26M shares for resale by Tempus Labs under prior license agreement

RECURSION PHARMACEUTICALS, INC.

Filed prospectus supplement to register 4,260,927 shares of Class A common stock for resale by Tempus Labs, Inc.
Shares were issued as payment for annual license fees under a Master Agreement dated Nov 2023.
Offering made under an exemption from registration; legal opinion filed as Exhibit 5.1.
Registration does not involve new issuance of shares; existing shares held by Tempus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.